CN111065733A - 靶向外泌体的方法 - Google Patents

靶向外泌体的方法 Download PDF

Info

Publication number
CN111065733A
CN111065733A CN201880057602.7A CN201880057602A CN111065733A CN 111065733 A CN111065733 A CN 111065733A CN 201880057602 A CN201880057602 A CN 201880057602A CN 111065733 A CN111065733 A CN 111065733A
Authority
CN
China
Prior art keywords
cells
gla
cancer
protein
vesicles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880057602.7A
Other languages
English (en)
Chinese (zh)
Inventor
T·赫米斯顿
M·巴宗
C·H·康泰格
J·哈迪
M·卡纳达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gladiator Biosciences Inc
Original Assignee
Gladiator Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gladiator Biosciences Inc filed Critical Gladiator Biosciences Inc
Publication of CN111065733A publication Critical patent/CN111065733A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0631—Mammary cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Urology & Nephrology (AREA)
CN201880057602.7A 2017-09-05 2018-09-05 靶向外泌体的方法 Pending CN111065733A (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201762554533P 2017-09-05 2017-09-05
US201762554530P 2017-09-05 2017-09-05
US62/554,530 2017-09-05
US62/554,533 2017-09-05
US201762569411P 2017-10-06 2017-10-06
US201762569403P 2017-10-06 2017-10-06
US62/569,411 2017-10-06
US62/569,403 2017-10-06
US201762584565P 2017-11-10 2017-11-10
US62/584,565 2017-11-10
US201762593014P 2017-11-30 2017-11-30
US62/593,014 2017-11-30
PCT/US2018/049619 WO2019050998A1 (en) 2017-09-05 2018-09-05 METHOD FOR TARGETING EXOSOMES

Publications (1)

Publication Number Publication Date
CN111065733A true CN111065733A (zh) 2020-04-24

Family

ID=63714024

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880056194.3A Pending CN111051500A (zh) 2017-09-05 2018-09-05 有效载荷递送至干细胞
CN201880057602.7A Pending CN111065733A (zh) 2017-09-05 2018-09-05 靶向外泌体的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201880056194.3A Pending CN111051500A (zh) 2017-09-05 2018-09-05 有效载荷递送至干细胞

Country Status (14)

Country Link
US (3) US20200407421A1 (enExample)
EP (3) EP3679127A1 (enExample)
JP (4) JP2020533404A (enExample)
KR (2) KR20200050975A (enExample)
CN (2) CN111051500A (enExample)
AU (2) AU2018330427A1 (enExample)
BR (2) BR112020004319A2 (enExample)
CA (2) CA3074291A1 (enExample)
IL (2) IL272908A (enExample)
MX (2) MX2020002250A (enExample)
PE (2) PE20201263A1 (enExample)
SG (2) SG11202001535RA (enExample)
WO (3) WO2019050998A1 (enExample)
ZA (2) ZA202000650B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112285195A (zh) * 2020-10-27 2021-01-29 江南大学 一种牛奶外泌体的特征性糖蛋白标志物和牛奶外泌体的特征性标志物分离方法
CN112553152A (zh) * 2020-10-27 2021-03-26 重庆市铂而斐细胞生物技术有限公司 一种快速提高脂肪间充质干细胞外泌体产量的方法
CN114940967A (zh) * 2022-05-09 2022-08-26 中山大学 母乳细胞外囊泡及其在制备骨修复材料中的应用
CN116421738A (zh) * 2023-02-28 2023-07-14 中国医科大学附属第一医院 捕获抗原的溶瘤病毒及其药物组合与制备和应用
TWI872888B (zh) * 2022-12-30 2025-02-11 財團法人工業技術研究院 用於穩定血液中游離核酸及/或外泌體核酸的組成物、含其之試劑與套組以及其用途

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3128999C (en) 2013-03-15 2023-09-12 GLAdiator Biosciences, Inc. Gla domains as targeting agents
JP2020530454A (ja) 2017-08-07 2020-10-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 安全な細胞治療薬を生成するためのプラットフォーム
EP3679127A1 (en) 2017-09-05 2020-07-15 GLAdiator Biosciences, Inc. Delivery of payloads to stem cells
CA3100035A1 (en) 2018-08-27 2020-03-05 Regeneron Pharmaceuticals, Inc. Use of raman spectroscopy in downstream purification
CN110036976B (zh) * 2019-05-08 2021-12-07 华南农业大学 一种阻断鸡禽白血病病毒垂直传播的方法及其应用
CN110423777A (zh) * 2019-07-23 2019-11-08 河南科技大学 无荧光染料标记外泌体及其制备方法
CN110711249B (zh) * 2019-09-19 2020-10-27 北京化工大学 一种溶酶体膜包覆纳米颗粒的制备方法
JP2022551486A (ja) * 2019-10-09 2022-12-09 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ イヌジステンパーウイルスのヘマグルチニンおよび融合ポリペプチド
KR102547446B1 (ko) * 2019-11-29 2023-06-26 서울대학교산학협력단 무표지 폴리다이아세틸렌 리포좀 기반의 엑소좀의 검출 방법
CN111803646B (zh) * 2020-06-04 2022-07-05 苏州大学 一种实体肿瘤联合治疗组合物
US20210393536A1 (en) * 2020-06-23 2021-12-23 Board Of Regents, The University Of Texas System Methods and compositions related to extracellular vesicles
KR102659285B1 (ko) * 2020-08-11 2024-04-22 경북대학교 산학협력단 암세포 유래 엑소좀에 선택적으로 결합하는 펩타이드 및 이의 용도
CN112516110B (zh) * 2020-10-13 2022-05-13 北京化工大学 一种细胞膜包覆纳米酶的方法
KR102285160B1 (ko) * 2020-12-24 2021-08-03 주식회사 타임바이오 전구세포에서 유래한 다기능성 엑소좀을 포함하는 피부염 예방 또는 치료용 약학적 조성물
KR102739746B1 (ko) * 2021-10-25 2024-12-10 인하대학교 산학협력단 바르토넬라 헨셀라이 유래 세포외 소포체를 이용한 바르토넬라 감염증 진단 방법
KR20240154736A (ko) * 2023-04-18 2024-10-28 가톨릭대학교 산학협력단 면역관문 억제제의 표적화된 전달을 위한 세포외소포체의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101426906A (zh) * 2004-09-10 2009-05-06 房芳 一类新颖的以蛋白质为基础的治疗用分子
WO2012087241A1 (en) * 2010-12-20 2012-06-28 Agency For Science, Technology And Research Method of purifying exosomes
CN105008397A (zh) * 2013-03-15 2015-10-28 拜尔健康护理有限责任公司 作为治疗试剂的Gla结构域
CN106414503A (zh) * 2014-03-11 2017-02-15 分子模板公司 包含邻近氨基酸端的志贺毒素a亚基效应子区和细胞靶向性免疫球蛋白型结合区的蛋白

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US5475085A (en) 1991-02-07 1995-12-12 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
JPH06505486A (ja) 1991-02-07 1994-06-23 モレキュメティクス，リミティド βターンおよびβバルジのコンフォメーション的に制限された模倣物およびそれらを含有するペプチド
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
US5329028A (en) 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
JP4116072B2 (ja) 1992-08-27 2008-07-09 バイオクローンズ（プロプライエタリー）リミテッド 逆向き、鏡像体および逆向き鏡像体合成ペプチド類似物
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
FI956352L (fi) 1993-06-30 1996-02-28 Univ Leiden Proteiini S:n deleetiovariantteja, joilta puuttuu C4BP:tä sitova aktiivisuus mutta joilla on APC-kofaktoriaktiivisuus koostumuksia ja terapeuttisia menetelmiä
US5597457A (en) 1995-01-23 1997-01-28 The Regents Of The University Of California System and method for forming synthetic protein crystals to determine the conformational structure by crystallography
US5840833A (en) 1995-10-27 1998-11-24 Molecumetics, Ltd Alpha-helix mimetics and methods relating thereto
US5929237A (en) 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
EP0965597A4 (en) 1996-12-27 2003-01-08 Mochida Pharm Co Ltd CELL MEMBRANE EFFECTIVE DRUGS
US6093573A (en) 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
ATE230614T1 (de) 1998-07-13 2003-01-15 Univ Texas Krebsbehandlung mit aminophospholipide bindenden, therapeutischen konjugaten
EP1105523A4 (en) 1998-08-13 2002-09-25 Wyeth Corp ESCHERICHIA COLI GDP-FUCOSE SYNTHETASE CRYSTALLINE STRUCTURE AND METHODS OF USE THEREOF
WO2000011206A1 (en) 1998-08-25 2000-03-02 The Scripps Research Institute Methods and systems for predicting protein function
US6801860B1 (en) 1999-02-15 2004-10-05 Genetics Institute, Llc Crystal structure of cPLA2 and methods of identifying agonists and antagonists using same
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
JP2002003407A (ja) 2000-06-20 2002-01-09 Medei Sci Puraningu:Kk ハイドロキシアパタイトカルシウム指向性薬物輸送担体
AU2002326580A1 (en) 2001-08-14 2003-03-03 Dana-Farber Cancer Institute, Inc. Computer-based methods of designing molecules
EP1644504B8 (en) 2003-06-19 2010-06-02 Bayer HealthCare LLC Factor vii or viia gla domain variants
DK1644412T4 (en) 2003-07-01 2018-11-12 Ucb Biopharma Sprl MODIFIED ANTIBODY-FAB FRAGMENTS
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
UA88272C2 (ru) * 2003-08-15 2009-10-12 Борд Оф Трастиз Оф Зе Юниверсити Оф Иллинойс Применение полипептидов семейства купредоксина в лечении рака
EP1744734A2 (en) 2004-02-20 2007-01-24 Novo Nordisk A/S Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
CA2567094C (en) 2004-05-26 2014-11-25 Schering Aktiengesellschaft Chimeric adenoviruses for use in cancer treatment
US7511016B2 (en) 2004-07-07 2009-03-31 Mosamedix B.V. Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
DK1781782T3 (da) 2004-08-17 2010-08-23 Csl Behring Gmbh Modificerede vitamin K-afhængige polypeptider
SG158919A1 (en) 2005-01-24 2010-02-26 Univ Texas Constructs binding to phosphatidylserine and their use in disease treatment
KR100987547B1 (ko) * 2006-06-01 2010-10-12 가톨릭대학교 산학협력단 냉동보관된 제대혈 줄기세포로부터 초기 세포사를 측정하는조성물, 키트 및 그 방법
US8216819B2 (en) 2006-12-22 2012-07-10 Psioxus Therapeutics Limited Generation of oncolytic adenoviruses and uses thereof
JP5130580B2 (ja) 2007-01-17 2013-01-30 独立行政法人放射線医学総合研究所 幹細胞における低線量被ばくの検出マーカー、及び該マーカーを用いる幹細胞での低線量被ばくレベルを推定又は検出する方法
UA101155C2 (ru) 2007-04-13 2013-03-11 Каталист Байосайенс, Инк. Модифицированный полипептид фактора vii (fvii) и его применение
KR100968839B1 (ko) 2008-02-25 2010-07-09 경북대학교 산학협력단 포스파티딜세린과 특이적으로 결합하는 폴리펩티드 및 이의용도
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
WO2010006136A2 (en) 2008-07-09 2010-01-14 Mayo Foundation For Medical Education And Research Adenovirus targeting
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
KR20110070887A (ko) 2008-10-02 2011-06-24 레스피버트 리미티드 Ｐ38 엠에이피 키나제 억제제
US8283167B2 (en) 2009-02-11 2012-10-09 Clear Vascular Inc. Preparation of annexin derivatives
ES2524974T3 (es) 2009-06-25 2014-12-16 The University Of North Carolina At Chapel Hill Moléculas del Factor VII quimérico
KR20120115602A (ko) 2010-01-26 2012-10-18 안트로제네시스 코포레이션 태반 줄기 세포를 사용한 골 관련 암의 치료
US10139420B2 (en) 2011-03-09 2018-11-27 ISNERM (Institut National de la Sante et de la Recherche Medicale) Methods for treating vaso-occlusive crisis using non-modified annexin V
CN103797028B (zh) * 2011-07-18 2017-08-25 Iba 股份有限公司 使靶细胞可逆染色的方法
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
TWI497845B (zh) 2012-07-18 2015-08-21 Murata Manufacturing Co Coaxial connector
US20150164800A1 (en) * 2012-07-25 2015-06-18 Xetrios Therapeutics, Inc. Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidyl serine
JP2014062084A (ja) 2012-09-19 2014-04-10 Georgetown Univ 標的化されたリポソーム
CN113831416A (zh) * 2014-06-11 2021-12-24 分子模板公司 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
CN105457032A (zh) 2014-08-11 2016-04-06 中国人民解放军军事医学科学院毒物药物研究所 靶向癌干细胞的碳纳米管-盐霉素药物递送系统、其制备方法及用途
WO2017118764A1 (en) 2016-01-07 2017-07-13 Thomas Brocker Novel approaches for the in vivo and in vitro visualization of dying cells
CN105567642B (zh) 2016-02-01 2019-07-12 中国科学院生物物理研究所 一种着色性干皮病人多能干细胞的制备方法
EP3679127A1 (en) 2017-09-05 2020-07-15 GLAdiator Biosciences, Inc. Delivery of payloads to stem cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101426906A (zh) * 2004-09-10 2009-05-06 房芳 一类新颖的以蛋白质为基础的治疗用分子
WO2012087241A1 (en) * 2010-12-20 2012-06-28 Agency For Science, Technology And Research Method of purifying exosomes
CN105008397A (zh) * 2013-03-15 2015-10-28 拜尔健康护理有限责任公司 作为治疗试剂的Gla结构域
CN105164152A (zh) * 2013-03-15 2015-12-16 拜尔健康护理有限责任公司 作为靶向试剂的gla结构域
CN106414503A (zh) * 2014-03-11 2017-02-15 分子模板公司 包含邻近氨基酸端的志贺毒素a亚基效应子区和细胞靶向性免疫球蛋白型结合区的蛋白

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHUN-LIANG SHIH等: "Development of a magnetic bead-based method for the collection of circulating extracellular vesicles" *
RUENN CHAI LAI等: "MSC secretes at least 3 EV types each with a unique permutation of membrane lipid, protein and RNA" *
WATARU NAKAI等: "A novel affinity-based method for the isolation of highly purified extracellular vesicles" *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112285195A (zh) * 2020-10-27 2021-01-29 江南大学 一种牛奶外泌体的特征性糖蛋白标志物和牛奶外泌体的特征性标志物分离方法
CN112553152A (zh) * 2020-10-27 2021-03-26 重庆市铂而斐细胞生物技术有限公司 一种快速提高脂肪间充质干细胞外泌体产量的方法
CN112285195B (zh) * 2020-10-27 2021-08-10 江南大学 一种牛奶外泌体的特征性糖蛋白标志物和牛奶外泌体的特征性标志物分离方法
CN114940967A (zh) * 2022-05-09 2022-08-26 中山大学 母乳细胞外囊泡及其在制备骨修复材料中的应用
CN114940967B (zh) * 2022-05-09 2024-05-31 中山大学 母乳细胞外囊泡及其在制备骨修复材料中的应用
TWI872888B (zh) * 2022-12-30 2025-02-11 財團法人工業技術研究院 用於穩定血液中游離核酸及/或外泌體核酸的組成物、含其之試劑與套組以及其用途
CN116421738A (zh) * 2023-02-28 2023-07-14 中国医科大学附属第一医院 捕获抗原的溶瘤病毒及其药物组合与制备和应用
CN116421738B (zh) * 2023-02-28 2024-03-19 中国医科大学附属第一医院 捕获抗原的溶瘤病毒及其药物组合与制备和应用

Also Published As

Publication number Publication date
ZA202001012B (en) 2021-03-31
CA3074291A1 (en) 2019-03-14
US20210062143A1 (en) 2021-03-04
WO2019050997A1 (en) 2019-03-14
WO2019050998A1 (en) 2019-03-14
MX2020002250A (es) 2020-09-18
PE20201263A1 (es) 2020-11-19
JP2020533021A (ja) 2020-11-19
KR20200050975A (ko) 2020-05-12
ZA202000650B (en) 2021-02-24
SG11202001536PA (en) 2020-03-30
AU2018328223A1 (en) 2020-03-12
EP3679128A1 (en) 2020-07-15
EP3679127A1 (en) 2020-07-15
US20200407421A1 (en) 2020-12-31
WO2019051002A1 (en) 2019-03-14
IL272908A (en) 2020-04-30
RU2020107182A3 (enExample) 2022-02-28
IL272942A (en) 2020-04-30
US20200407422A1 (en) 2020-12-31
EP3679129A1 (en) 2020-07-15
RU2020107182A (ru) 2021-10-06
JP2024073589A (ja) 2024-05-29
CA3074678A1 (en) 2019-03-14
CN111051500A (zh) 2020-04-21
AU2018330427A1 (en) 2020-04-02
MX2020002442A (es) 2020-07-13
JP2020533404A (ja) 2020-11-19
BR112020003945A2 (pt) 2020-09-08
US11981723B2 (en) 2024-05-14
PE20201462A1 (es) 2020-12-17
SG11202001535RA (en) 2020-03-30
BR112020004319A2 (pt) 2020-09-08
JP7365704B2 (ja) 2023-10-20
KR20200050961A (ko) 2020-05-12
JP2020533976A (ja) 2020-11-26

Similar Documents

Publication Publication Date Title
CN111065733A (zh) 靶向外泌体的方法
EP3261677B1 (en) Targeted transplantation of mitochondria to hepatocytes
Sabu et al. Nanomedicines targeting glioma stem cells
AU2019209502B2 (en) Langerin+ Cell Targeting
TW201247710A (en) Tumor-targeting peptides and their uses in detecting and treating cancers
Malle et al. Programmable RNA loading of extracellular vesicles with toehold-release purification
WO2021036793A1 (en) Pyroptosis-induced immunotherapy
RU2781640C2 (ru) Способ адресного воздействия на экзосомы
RU2795155C1 (ru) Доставка полезной нагрузки к стволовым клеткам
Thomas Live Biotherapeutics and Outer Membrane derived Vesicles for Anticancer Therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20200424

RJ01 Rejection of invention patent application after publication